Forthcoming Special Issues
Nordic POP: Patient-Oriented Products
Prescribing medicine today is based on a one-size-fits-all principle. There is, however, a clear need for more personalized solutions in several critical therapy areas. Recent developments within the genomics and diagnostic fields has enabled development of new innovative medicinal products relying on a combination of diagnostic tools and personalized doses. This approach is paving the way towards future health care systems based on personalized medicines. Limited attention has been given to the personalized end-product requirements for optimal therapeutic performance. Complex dosing regimens will require advances in product design to enable precise administration of the most appropriate dose. Innovations in pharmaceutical product design are required to alleviate potential problems. This Special Issue will present innovative patient oriented products, including new product design principles, novel methods for better understanding of the product performance, and a paradigm shift in the manufacturing of these products. With these approaches, new types of personalized treatment strategies can be designed and the individual variation between patients can be taken into account
Guest editors:
- Prof. Gøril Eide Flaten, M.Pharm, PhD
Drug Transport and Delivery research group, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway - Dr. Alexandra Teleki, Associate Professor
Uppsala University
Science for Life Laboratory, Department of Pharmacy
P.O. Box 580
751 23 Uppsala, Sweden
Areas of expertise: pharmaceutical nanotechnology, oral drug delivery, microencapsulation, formulation, drug development, inorganic nanoparticles, gastrointestinal diseases - Prof. Jessica Rosenholm, D.Sc.(Tech.)
Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University
Turku, Finland
Special issue information:
Prescribing medicine today is based on a one-size-fits-all principle. There is, however, a clear need for more personalized solutions in several critical therapy areas. Recent developments within the genomics and diagnostic fields has enabled development of new innovative medicinal products relying on a combination of diagnostic tools and personalized doses. This approach is paving the way towards future health care systems based on personalized medicines. Limited attention has been given to the personalized end-product requirements for optimal therapeutic performance. Complex dosing regimens will require advances in product design to enable precise administration of the most appropriate dose. Innovations in pharmaceutical product design are required to alleviate potential problems. This Special Issue will present innovative patient oriented products, including new product design principles, novel methods for better understanding of the product performance, and a paradigm shift in the manufacturing of these products. With these approaches, new types of personalized treatment strategies can be designed and the individual variation between patients can be taken into account
Manuscript submission information:
The Journal's submission system will be open for submissions to our Special Issue from 15 August 2022. When submitting your manuscript please select the article type “VSI: 'NordicPOP'. Please submit your manuscript before 31 Mar 2023.
All submissions deemed suitable to be sent for peer review will be reviewed by at least two independent reviewers. Once your manuscript is accepted, it will go into production, and will be simultaneously published in the current regular issue and pulled into the online Special Issue. Articles from this Special Issue will appear in different regular issues of the journal, though they will be clearly marked and branded as Special Issue articles.
The Guide for Authors and link to submit your manuscript is available on the Journal’s homepage at: https://www.journals.elsevier.com/european-journal-of-pharmaceutical-sciences
Inquiries, including questions about appropriate topics, may be sent electronically to Martin BrandI at [email protected]
Keywords:
(personalized medicine) OR (personalized medicines) OR (precision medication) AND (personalized dosing) AND (customized drug delivery) AND (drug delivery barrier) OR (drug delivery barriers) AND (product design) AND (drug manufacturing) AND (analytics) AND (synchrotron) AND (modeling) AND (simulation) …
Why publish in this Special Issue?
- Special Issue articles are published together on ScienceDirect, making it incredibly easy for other researchers to discover your work.
- Special content articles are downloaded on ScienceDirect twice as often within the first 24 months than articles published in regular issues.
- Special content articles attract 20% more citations in the first 24 months than articles published in regular issues.
- All articles in this special issue will be reviewed by no fewer than two independent experts to ensure the quality, originality and novelty of the work published.
Learn more about the benefits of publishing in a special issue: https://www.elsevier.com/authors/submit-your-paper/special-issues
Interested in becoming a guest editor? Discover the benefits of guest editing a special issue and the valuable contribution that you can make to your field: https://www.elsevier.com/editors/role-of-an-editor/guest-editors
Colon drug delivery
During the past 30 years, a considerable amount of work has been performed to design delivery systems for targeting drugs to the large intestine. This is an interesting formulation strategy for treatment of colonic pathologies like Crohn’s disease, ulcerative colitis or colon cancer. Moreover, colon-targeted drug formulations will potentially also enable oral administration of macromolecules, like (poly)peptides, antibodies or oligonucleotides. The focus of this special issue is on the formulation and manufacturing of colon drug delivery systems, as well as on the biopharmaceutical aspects related to colon drug delivery.
Guest editors:
Dr. Jody Voorspoels
PhD in Pharmaceutics (Ghent University, 1997), CSO Eurofins CDMO | Eurofins Amatsigroup NV, Ghent, Belgium
Areas of expertise: formulation development, colon drug delivery, poorly soluble drugs
Prof. Dr. Guy Van den Mooter
PhD in Pharmaceutics (KULeuven, 1994)
Laboratory of Drug Delivery and Disposition
Department of Pharmaceutical and Pharmacological Sciences
Faculty of Pharmaceutical Sciences
University of Leuven (KULeuven)
Leuven, Belgium
Areas of expertise: amorphous systems, colon drug delivery, poorly soluble drugs, solid state analysis
Special issue information:
During the past 30 years, a considerable amount of work has been performed to design delivery systems for targeting drugs to the large intestine. This is an interesting formulation strategy for treatment of colonic pathologies like Crohn’s disease, ulcerative colitis or colon cancer. Moreover, colon-targeted drug formulations will potentially also enable oral administration of macromolecules, like (poly)peptides, antibodies or oligonucleotides. The focus of this special issue is on the formulation and manufacturing of colon drug delivery systems, as well as on the biopharmaceutical aspects related to colon drug delivery
Manuscript submission information:
The Journal's submission system will be open for submissions to our Special Issue from 01 Feb 2023. When submitting your manuscript please select the article type “VSI: Colon drug delivery”. Please submit your manuscript before 31 Jul 2023.
All submissions deemed suitable to be sent for peer review will be reviewed by at least two independent reviewers. Once your manuscript is accepted, it will go into production, and will be simultaneously published in the current regular issue and pulled into the online Special Issue. Articles from this Special Issue will appear in different regular issues of the journal, though they will be clearly marked and branded as Special Issue articles.
The Guide for Authors and link to submit your manuscript is available on the Journal’s homepage at: https://www.journals.elsevier.com/european-journal-of-pharmaceutical-sciences
Inquiries, including questions about appropriate topics, may be sent electronically to Prof Guy Van den Mooter at [email protected]
Keywords:
Colon drug delivery
Why publish in this Special Issue?
- Special Issue articles are published together on ScienceDirect, making it incredibly easy for other researchers to discover your work.
- Special content articles are downloaded on ScienceDirect twice as often within the first 24 months than articles published in regular issues.
- Special content articles attract 20% more citations in the first 24 months than articles published in regular issues.
- All articles in this special issue will be reviewed by no fewer than two independent experts to ensure the quality, originality and novelty of the work published.
Learn more about the benefits of publishing in a special issue: https://www.elsevier.com/authors/submit-your-paper/special-issues
Interested in becoming a guest editor? Discover the benefits of guest editing a special issue and the valuable contribution that you can make to your field: https://www.elsevier.com/editors/role-of-an-editor/guest-editors
Biologically Inspired Engineering of the Lungs: Advances in Preclinical Pulmonary Pathobiology Models for Translational and Therapeutic Applications
This Special Issue invites contributions covering both bottom-up and top-bottom translational bioengineering approaches that merge lung biology, tissue engineering, respiratory cellular models and pulmonary medicine to allow accelerated translation of findings from preclinical setting to clinic.
Guest editors:
Josué Sznitman, Technion – Israel Institute of Technology
Kambez Benam, University of Pittsburgh
Carsten Ehrhardt, Trinity College Dublin
Special issue information:
Disorders of the respiratory system are a huge public health burden and pose a substantial socio-economic impact. Emerging and re-merging respiratory viral infections, antimicrobial-resistant bacterial infections, debilitating and often associated with poor survival lung cancers, chronic obstructive pulmonary disease (COPD), severe corticosteroid non-responsive asthma epitomize a few acute and chronic pulmonary conditions. The dire reality of respiratory afflictions has been further exacerbated with the coronavirus disease 2019 (COVID-19) pandemic that can lead to respiratory distress syndrome and severe pathologies. As such, there is a pressing need for new therapeutic strategies for lung pulmonary disorders. The pace and success of drug development is heavily dependent on availability of human-relevant lung tissue- and organ-mimicking physiological systems. This Special Issue invites contributions covering both bottom-up and top-bottom translational bioengineering approaches that merge lung biology, tissue engineering, respiratory cellular models and pulmonary medicine to allow accelerated translation of findings from preclinical setting to clinic.
Publication cost:
As an open access journal with no subscription charges, a fee (Article Publishing Charge, APC) is payable by the author or research funder to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone. The Article Publishing Charge(APC) for this journal is USD 2300, excluding taxes. All the published articles are eligible for 30% discount and hence bears a revised APC of USD 1610 (excluding tax).
Manuscript submission information:
- Submission site: https://www.editorialmanager.com/phasci/default1.aspx
- To ensure manuscript is correctly included into the special issue, please select "VSI: Bioinspired Lung Models" as the name of the article type
- Submission deadline: 30-April-2023
- To check for the correctness of the manuscript, reach out to Josué Sznitman ([email protected])
Why publish in this Special Issue?
- Special Issue articles are published together on ScienceDirect, making it incredibly easy for other researchers to discover your work.
- Special content articles are downloaded on ScienceDirect twice as often within the first 24 months than articles published in regular issues.
- Special content articles attract 20% more citations in the first 24 months than articles published in regular issues.
- All articles in this special issue will be reviewed by no fewer than two independent experts to ensure the quality, originality and novelty of the work published.
Learn more about the benefits of publishing in a special issue: https://www.elsevier.com/authors/submit-your-paper/special-issues
Interested in becoming a guest editor? Discover the benefits of guest editing a special issue and the valuable contribution that you can make to your field: https://www.elsevier.com/editors/role-of-an-editor/guest-editors
Parenteral drug delivery and manufacturing technology
The special issue on parenteral formulations has as a scope to collect a wide variety of papers in the field, which could be related to formulation studies, manufacturing sciences, preservation, solubilizations, extended release technologies, packing, devices etc.
Submission of original research articles, review articles, mini-reviews, commentaries, and short commutations are encouraged.
Guest editors:
René Holm, University of Southern Denmark
Christopher Rhodes, Baywind Bioventures
Special issue information:
By linguistic definition parenteral drug delivery covers all drug administration routes that is non-oral, e.g. topical to the skin or eye, buccal, intranasal, intravenous etc., hence the area covers a high diversity with respect to dosage forms and administration routes. Despite these diversities many of the dosage forms administered parenterally have a number of similarities from both a formulation, manufacturing and packing perspective.
The oral route is preferred due to the ease of administration to most patients, however, not all compounds can be delivered orally due to the digestive system or low intestinal permeability in the gastrointestinal tract, as is in general the case for peptides and similar biomolecules. Here parenteral administration is the only way of administration that may deliver the amount of compound needed to achieve the therapeutically concentrations needed. With the development in molecular biology more and more drug compounds are identified in this class, hence despite the huge improvements in oral drug delivery, which even allows some absorption of some peptides orally there is still a need for parenteral drug delivery in a lot of cases, why the area have a large interest for health care improvements in general, why it is a very important field for pharmaceutical sciences.
The special issue on parenteral formulations has as a scope to collect a wide variety of papers in the field, which could be related to formulation studies, manufacturing sciences, preservation, solubilizations, extended release technologies, packing, devices etc.
Submission of original research articles, review articles, mini-reviews, commentaries, and short commutations are encouraged.
Publication cost:
As an open access journal with no subscription charges, a fee (Article Publishing Charge, APC) is payable by the author or research funder to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone. The Article Publishing Charge(APC) for this journal is USD 2300, excluding taxes. All the published articles are eligible for 30% discount and hence bears a revised APC of USD 1610 (excluding tax).
Manuscript submission information:
- Submission site: https://www.editorialmanager.com/phasci/default.aspx
- Manuscript could be submitted from 1st May 2022 until 31st December 2022
- To ensure the manuscript is correctly included into the special issue, please select "VSI:Parenteral formulations" as the name of the article type
Why publish in this Special Issue?
- Special Issue articles are published together on ScienceDirect, making it incredibly easy for other researchers to discover your work.
- Special content articles are downloaded on ScienceDirect twice as often within the first 24 months than articles published in regular issues.
- Special content articles attract 20% more citations in the first 24 months than articles published in regular issues.
- All articles in this special issue will be reviewed by no fewer than two independent experts to ensure the quality, originality and novelty of the work published.
Learn more about the benefits of publishing in a special issue: https://www.elsevier.com/authors/submit-your-paper/special-issues
Interested in becoming a guest editor? Discover the benefits of guest editing a special issue and the valuable contribution that you can make to your field: https://www.elsevier.com/editors/role-of-an-editor/guest-editors
Approaches for targeted protein degradation: From biology to drug development
The special issue on targeted protein degradation has as a scope to collect a wide variety of papers in the field, which could be related to molecular and structural biology, medicinal chemistry, and pharmaceutical development.
Guest editors:
Dr Christoph Saal, Merck Group, Darmstadt
Dr. Catherine Lindon, University of Cambridge
Prof. Carlos Galdeano, University of Barcelona
Prof. Elmar Wolf, University of Würzburg
Dr. Simon Geissler, Merck Healthcare KGaA
Special issue information:
Targeted protein degradation is a rapidly emerging modality for novel therapies. Proteins are selectively degraded using the cell’s natural ubiquitin proteasome pathway. Targeted protein degradation is initiated via formation of a ternary complex between the protein to be degraded, an E3 ligase which carries out ubiquitinylation of the targeted protein and a molecule which links the protein to be degraded and the E3 ligase, for example, proteolysis targeting chimeras (Protacs) or molecular glues.
Targeted protein degradation represents a fundamental alternative approach compared to well established therapeutical concepts such as inhibition of target proteins. This special issue summarizes advances and challenges in the development of targeted protein degraders within different disciplines such as biology, chemistry, and pharmaceutical development.
The special issue on targeted protein degradation has as a scope to collect a wide variety of papers in the field, which could be related to molecular and structural biology, medicinal chemistry, and pharmaceutical development.
Submission of original research articles, review articles, mini-reviews, commentaries, and short commutations are encouraged.
Publication cost:
As an open access journal with no subscription charges, a fee (Article Publishing Charge, APC) is payable by the author or research funder to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone. The Article Publishing Charge(APC) for this journal is USD 2300, excluding taxes. All the published articles are eligible for 30% discount and hence bears a revised APC of USD 1610 (excluding tax).
https://www.elsevier.com/journals/european-journal-of-pharmaceutical-sciences/0928-0987/open-access-information
Manuscript submission information:
- Submission site: https://www.editorialmanager.com/phasci/default.aspx
- Manuscript could be submitted from 15th May 2022 until 31st January 2023
- To ensure the manuscript is correctly included into the special issue, please select "VSI: Targeted protein degradation" as the name of the article type
- You are invited to submit your manuscript at any time before the submission deadline. For any inquiries about the appropriateness of contribution topics, please contact Dr. Christoph Saal, [email protected]
Why publish in this Special Issue?
- Special Issue articles are published together on ScienceDirect, making it incredibly easy for other researchers to discover your work.
- Special content articles are downloaded on ScienceDirect twice as often within the first 24 months than articles published in regular issues.
- Special content articles attract 20% more citations in the first 24 months than articles published in regular issues.
- All articles in this special issue will be reviewed by no fewer than two independent experts to ensure the quality, originality and novelty of the work published.
Learn more about the benefits of publishing in a special issue: https://www.elsevier.com/authors/submit-your-paper/special-issues
Interested in becoming a guest editor? Discover the benefits of guest editing a special issue and the valuable contribution that you can make to your field: https://www.elsevier.com/editors/role-of-an-editor/guest-editors